Dr. Menzel joined TCR2 in 2016 as a Director and Chief Executive Officer. He has over 20 years of experience in building healthcare businesses and leading high-performing teams of professionals. He has also led multiple corporate transactions, including private financings, initial public offerings, licensing and M&A. Prior to TCR2, he was the Chief Strategy Officer at Axcella Health, the Chief Financial Officer at DaVita Healthcare (NYSE: DVA), and the Chief Operating Officer at Regulus Therapeutics (NASDAQ:RGLS). Dr. Menzel also had global leadership roles in running the biotechnology practices at Goldman Sachs and Credit Suisse. In addition, he was a consultant with Bain & Company. Dr. Menzel earned his PhD from the University of Cambridge for studying the regulation of oncogenes in immune cells. He also has a MBA from the Stanford Graduate School of Business.